Cart
sales@molnova.com
Glenzocimab
CAS No. 2101829-58-5
Glenzocimab( —— )
Catalog No. M36897 CAS No. 2101829-58-5
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 439 | Get Quote |
|
| 5MG | 661 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1371 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2448 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGlenzocimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionGlenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
-
DescriptionGlenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.
-
In Vitro——
-
In VivoAnimal Model:Cynomolgus monkeysDosage:1-8 mg/kg Administration:I.v.Result:Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2101829-58-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. ?
molnova catalog
related products
-
Saucerneol
Saucerneol has significant cardiovascular effects such as vasorelaxant and negative inotropic actions.
-
SAH
SAH is an inhibitor for the METTL3-METTL14 heterodimer complex (METTL3-14 IC50: 0.9 μM).
-
Phenibut (hydrochlor...
Phenibut (hydrochloride)?is a GABA mimetic that acts as an agonist at GABAB receptors, blocks α2δ subunit-containing voltage-gated calcium channels, stimulates dopamine receptors, and inhibits the actions of β-phenethylamine.
